Tim Moore
BIOLIFE SOLUTIONSAbout Tim Moore
Tim Moore (age 64) is an independent director of BioLife Solutions (BLFS) and has served on the Board since September 2022 . He brings three decades of biopharmaceutical manufacturing and operations leadership, with prior senior roles at Allogene Therapeutics, Instil Bio, PACT Pharma, Kite (a Gilead company), Genentech, and ZLB Behring; he holds a B.S. in Chemical Engineering (University of Tulsa) and an M.S. in Engineering Management (Northwestern University) . Moore is currently a member of ISPE and PDA, has participated in BioPhorum’s Executive Committee, and serves on the Board of Cerus Corporation (CERS), adding domain expertise and external perspective to BLFS governance . The Board has determined Moore is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Allogene Therapeutics | EVP, Chief Technical Operations | Through Feb 2025 | Led technical ops for allogeneic CAR‑T; manufacturing, quality, supply chain |
| Instil Bio | Chief Operating Officer | Through Dec 2022 | COO for TIL cell therapy; operational scaling |
| PACT Pharma | President & COO | Oct 2019 – Sep 2022 | Built individualized T‑cell manufacturing capabilities |
| Kite (Gilead) | EVP, Technical Operations | Since Mar 2016 (prior role) | Launched Yescarta; global expansion across US/EU/Asia; end‑to‑end ops |
| Genentech | SVP, Head Global Technical Ops – Biologics; SVP Global Supply Chain & Engineering | 2007–2010 | Oversaw >7,500 professionals across 10 sites and 37 CMOs; 20+ biologics families |
| ZLB Behring (Aventis Behring) | VP, Operations | Prior to Genentech | Plasma biologics operations leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Cerus Corporation (CERS) | Board Member | Current | Public company board; blood safety technologies |
| ISPE, PDA, BioPhorum | Member; Exec Committee participant (BioPhorum) | Ongoing | Industry associations; technical and manufacturing best‑practice networks |
Board Governance
- Independence: Board affirmed Moore is independent (Nasdaq 5605(a)(2)) .
- Committee assignments: Compensation Committee member; Governance & Nominating Committee member .
- Chair roles: None; Compensation Chair is Amy DuRoss; Governance & Nominating Chair is Joydeep Goswami .
- Attendance: Board held 14 meetings in 2024; each incumbent director attended at least 75% of required meetings .
- Engagement: Signed Compensation Committee report with DuRoss, Ellingson, Hunt, evidencing active oversight of executive and director pay .
Fixed Compensation
| Item | 2024 Amount/Terms | Notes |
|---|---|---|
| Annual cash retainer | $60,000 | Standard non‑employee director retainer |
| Chair fees | $0 | Moore not a chair in 2024; Chair rates listed separately |
| RSU grant (2024) | $195,543 accounting grant‑date FV | Fixed $180,000 nominal value at Jan 2, 2024; effective grant Mar 8, 2024 at $17.36 |
| Unvested RSUs (12/31/2024) | 11,264 units | One‑year vest from grant date (standard policy) |
| 2026 policy (effective Jan 1, 2026) | Cash retainer $70,000; annual RSUs at $180,000; optional stock in lieu of cash; Chair retainer Audit $20k, Comp $15k, Gov $10k; Lead Independent $40k | Policy adopted in early 2025 |
Performance Compensation
Moore’s director equity is time‑based RSUs; there are no disclosed performance metrics tied to director compensation . As a Compensation Committee member, Moore oversaw executive pay design and performance metrics; BLFS’s 2024 corporate objectives and outcomes (executive plan) were:
| Metric | Weight | Target | Result | Payout Contribution |
|---|---|---|---|---|
| Revenue | 30% | $76M | ~$82M achieved; ≥$81M max threshold | 39% of Target Award |
| Adjusted EBITDA Margin (ex‑exec bonus) | 30% | 13% | 21% achieved; ≥16% max threshold | 39% of Target Award |
| Remediation of material weaknesses | 20% | Full remediation, no new MWs | 2023 MWs remediated; 1 new MW in 2024 | 10% of Target Award |
| NetSuite MRP module (Media) | 20% | Implement | Not fully implemented | 0% of Target Award |
| Aggregate payout determined at 88% of target for NEOs . |
Other Directorships & Interlocks
| Company | Role | Interlock/Conflict Notes |
|---|---|---|
| Cerus (CERS) | Board Member | No BLFS related‑party transactions >$120,000 since Jan 1, 2024; Board confirms independence and no compensation committee interlocks requiring disclosure . |
Expertise & Qualifications
- Thirty+ years leading large‑scale biologics and cell therapy operations, global tech ops, supply chain, and quality .
- Degrees: B.S. Chemical Engineering (Tulsa); M.S. Engineering Management (Northwestern) .
- Industry associations: ISPE, PDA; BioPhorum Executive Committee participation .
- Skill relevance to BLFS: Deep cell/gene therapy manufacturing and supply chain expertise aligns with BLFS’s bioproduction focus .
Equity Ownership
| Holder | Beneficial Shares | % of Outstanding | Notes |
|---|---|---|---|
| Tim Moore | 29,897 | <1% | Based on 47,835,214 shares outstanding (as of 6/23/2025) . |
| Unvested RSUs (director grant) | 11,264 | N/A | As of 12/31/2024; standard one‑year vest . |
No pledging/hedging disclosures specific to directors appear; BLFS maintains an insider trading policy covering directors, officers, employees, and consultants .
Board Governance
| Attribute | Status | Evidence |
|---|---|---|
| Independence | Independent | Board determination |
| Committee Memberships | Compensation; Governance & Nominating | Committee table |
| Chair Roles | None | Committee table |
| Attendance | ≥75% of meetings | Board/committee meeting disclosure for incumbents |
| Compensation Oversight | Signed Comp Committee report | Committee report |
Governance Assessment
- Strengths: Independence affirmed; meaningful sector expertise (manufacturing, CGT operations) on two key committees; active involvement in compensation oversight; attendance threshold met by all incumbents; no related‑party transactions involving Moore over $120k disclosed .
- Alignment: Director pay mix includes cash retainer and equity RSUs that vest with continued service; unvested RSUs tie value to share price performance, supporting alignment .
- Risks/Red Flags: Change‑in‑control acceleration for director RSUs (accelerate upon death, disability, or change in control) may be viewed as standard but can reduce retention incentives post‑transaction . No attendance deficiencies, related‑party exposures, or Section 16 delinquency noted for Moore; compensation committee interlock risks not present per disclosure .
- Net: Governance profile supports investor confidence; Moore’s operational depth in CGT is accretive to board effectiveness for BLFS’s bioproduction strategy .